WS

West Pharmaceutical Services, Inc.

WSTHealthcareNASDAQ

Medical Instruments & Supplies

PriceMA150MA200
Loading chart…
End-of-day data · ScananceOpen live chart on TradingView ↗
Indicator snapshot · Today
Premium
Today's indicator reading is locked

Free plan shows historical signals only. Upgrade to see this ticker's current MA150, MA200, RSI, and MACD readings.

Upgrade to see today →
Financials · Annual
Revenue
$3.07B
+6.3% YoY
Net Income
$493.7M
+0.2% YoY
EBITDA
$772.8M
+3.9% YoY
Free Cash Flow
$277.9M

Scan Results

Daily timeframe
DateIndicatorDetails
Aug 31 MACD Negative CrossoverHistogram -1.1690, negative momentum
Aug 29 MACD Negative CrossoverHistogram -1.1690, negative momentum
About West Pharmaceutical Services, Inc.

West Pharmaceutical Services, Inc. operates in the Medical Instruments & Supplies space. West Pharmaceutical Services, Inc. The $23.93B market capitalization puts WST squarely in large-cap range for its industry. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific.

Where WST stands vs its 150-day and 200-day moving averages

As of the August 31, 2026 close, WST finished 12.95% above its 150-day moving average ($298.79) and 15.74% above its 200-day moving average ($291.57). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.

Is WST overbought or oversold?

At the August 31, 2026 close, WST's RSI(14) was 32.0, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.

Key stats
Market Cap$23.93B
P/E (TTM)43.87
Fwd P/E34.12
EPS$7.75
Beta1.14
52W Change+36.7%
Dividend Yield0.26%
ROE19.1%
Analysis

West Pharmaceutical Services, Inc. holds $435.8M in cash against $316.5M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Annual free cash flow of $277.9M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. Return on equity stands at 19.1%, which is strong for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Return on assets of 11.4% further supports the picture of efficient asset utilization. Revenue has been relatively flat, moving from $2.89B (2022) to $3.07B (2025).

Investors considering West Pharmaceutical Services, Inc. should weigh the typical risks associated with WST's sector, size, and financial profile against their own risk tolerance and investment objectives. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence West Pharmaceutical Services, Inc.'s trajectory.

Links
More Healthcare stocks
Browse all stocks →
Not financial advice. Scanance shows end-of-day technical indicators (not real-time prices) for information only. Results can be wrong; past performance does not guarantee future results.PrivacyTerms